ACCESS CONFIRMATION21+ · RESEARCH USE ONLY
Trenix Labs provides information about products intended exclusively for controlled laboratory and research purposes.
Age eligibility does not make any product appropriate for personal, human, veterinary, diagnostic, or therapeutic use.
SMX · RESEARCH PROFILE
Synthetic research peptide
A synthetic ACTH-fragment analog studied mainly in preclinical and international research involving melanocortin-related, neurotrophic, and transcriptomic signaling.
KEY HIGHLIGHTS
ACTH(4–7)-related peptide
Designed without full ACTH activity
Neurotrophin and transcriptomic models
Mechanism remains multifactorial
Not FDA-approved in the U.S.
EXPLORE SEMAX
Semax is a synthetic peptide based on the ACTH(4–7) fragment with an added Pro-Gly-Pro sequence. It was designed for peptide-signaling research without the full adrenal-stimulating activity of intact ACTH. It has international research and use history but is not FDA-approved in the United States.
Proposed mechanisms include changes in neurotrophin expression, melanocortin-associated signaling, neurotransmitter systems, and broader gene-expression programs. Recent rat transcriptomic work found numerous altered genes after exposure, underscoring that Semax may produce network-level effects rather than one fully defined receptor mechanism.
Researchers use Semax in cellular and animal models involving neural stress, ischemia-related pathways, neurotrophins, synaptic signaling, and transcriptomic responses. Model choice and timing matter because a short-lived peptide signal can lead to later gene-expression changes that differ across tissues.
Semax is an ACTH-fragment analog engineered to separate peptide-signaling questions from the endocrine behavior of full-length ACTH. The added Pro-Gly-Pro segment changes stability and biological behavior, so findings about ACTH or other melanocortins cannot be transferred directly.
EVIDENCE BOUNDARY
Mechanistic evidence is largely preclinical, and results from international formulations do not establish equivalence to a research vial. FDA has identified potential immunogenicity and impurity concerns for certain compounded routes. U.S. safety and effectiveness are not established.
READ THE SOURCES
These links provide context for the pathways and limitations described above. Studies of an ingredient or related molecule do not validate a specific Trenix batch or blend.
LOCAL FOLLOW-UP
Submit a research-product request and our local team will follow up about availability and documentation.